Home・Akcijų sąrašas・Compugen Ltd

Compugen Ltd

Uždarymo kaina

2.57 1.18

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.57

Max

2.59

Pagrindiniai rodikliai
By Trading Economics
Pajamos	663K -7M
Pardavimai	426K 2.6M
P/E Sektoriaus vid.	6.737 56.659
Pelnas, tenkantis vienai akcijai	-0.07
Pelno marža	-269.254
Darbuotojai	75
EBITDA	665K -7M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+93.05% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-09

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	17M 242M
Ankstesnė atidarymo kaina	1.39
Ankstesnė uždarymo kaina	2.57

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-06 23:51; UTC

ECB President Lagarde's Upcoming Speech on September 9, 2026, Expected to Address Interest Rates and Inflation Amidst Euro Area Economic Uncertainties.

2026-09-06 23:51; UTC

Correlated Moves

Avalanche is trading higher, boosted by strong performance in correlated assets like Ethereum. It is currently 8.96% above its 20-day moving average.

2026-09-06 23:41; UTC

Investors Brace for September 11 CPI Release Amid Rising Inflation Concerns and Economic Uncertainties

2026-09-06 23:41; UTC

Investors Brace for Key CPI Release on September 11, Anticipating Impact on Inflation Trends and Market Dynamics.

2026-09-06 23:41; UTC

U.S. Inflation Rate Expected to Stabilize at 3.4% Amid Market Caution and Potential Fed Interest Rate Hikes

2026-09-06 23:41; UTC

U.S. Core Inflation Rate Expected at 2.4% Amid Rising Market Volatility and Anticipated Fed Rate Hike Discussions

2026-09-06 23:41; UTC

Core Inflation Rate Expected to Rise 0.2% in August, Sparking Optimism Among Traders Ahead of September Release

2026-09-06 23:41; UTC

U.S. Inflation Rate Expected to Rise by 0.4% in August, Heightening Concerns Over Interest Rate Hikes Amid Strong Job Growth

2026-09-06 23:31; UTC

U.S. Core Producer Prices Expected to Rise 0.3% in August Amid Inflation Concerns and Potential Fed Rate Hikes

2026-09-06 23:21; UTC

U.S. Producer Price Inflation Expected to Rise 0.3% Amid Caution Over Potential Fed Rate Hikes

2026-09-06 23:11; UTC

Euro Area's Deposit Facility Rate Expected to Rise to 0.025% Amid Investor Anticipation of Economic Catalysts

2026-09-06 22:41; UTC

Australia's Westpac Consumer Confidence report set for September 8, 2026, shows cautious optimism amid inflation concerns and rising investor confidence.

2026-09-06 22:31; UTC

Mexican Inflation Rate Expected to Continue Declining Trend Ahead of September 9 Release, Boosting Market Optimism.

2026-09-06 22:31; UTC

Mexico's Inflation Rate Release on September 9, 2026 Expected to Influence Market Dynamics Amid Global Economic Sentiment.

2026-09-06 22:31; UTC

Australia's Westpac Consumer Confidence Index set for release on September 8, amid mixed market expectations and rising optimism following increased buying activity.

2026-09-06 22:21; UTC

MBA 30-Year Mortgage Rate Release on September 9, 2026, Expected to Show Continued Upward Pressure Amid Inflation and Fed Policy Concerns.

2026-09-06 22:11; UTC

Brazil's Central Bank to Provide Key Insights on Monetary Policy Direction in Upcoming Interest Rate Readout Amid Market Uncertainty

2026-09-06 22:01; UTC

Japan's GDP Growth Forecasted at +1.1% for Q2 2026 Amid Cautious Optimism in Economic Recovery

2026-09-06 22:01; UTC

Japan's GDP Growth Rate Expected at +0.4% Amidst Rising Market Confidence and Global Economic Discussions

2026-09-06 21:51; UTC

Turkey's Central Bank Expected to Maintain 37% Interest Rate Amid Inflation Concerns Ahead of September Decision.

2026-09-06 21:51; UTC

UK Housing Market Faces Continued Pressure as RICS House Price Balance Forecast Improves Slightly to -0.28% Amid Weak Buyer Demand

2026-09-06 21:31; UTC

South Korea's August 2026 unemployment rate release on September 8 sparks cautious optimism amid recent job gains and inflationary pressures.

2026-09-06 21:11; UTC

UK Retail Sales Monitor YoY for August 2026 Expected to Show Modest 1.2% Increase Amid Cautious Consumer Sentiment and Economic Challenges

2026-09-06 21:01; UTC

Spain's Consumer Confidence report on September 8, 2026, shows rising optimism with an index increase to 81.2 amid recovering market sentiment and geopolitical concerns.

2026-09-06 21:01; UTC

Cautious Market Sentiment Ahead of South Africa's Q2 GDP Growth Rate Release Amid Global Economic Fluctuations

2026-09-06 21:01; UTC

South Africa's GDP Growth Rate Release on September 8, 2026 Sparks Market Optimism Amid Global Economic Factors.

2026-09-06 20:21; UTC

Japan's Current Account data set for release on September 7, 2026, forecasts a surplus of JPY 2.87 trillion amid cautious investor sentiment due to historical volatility in outcomes.

2026-09-06 19:01; UTC

API Crude Oil Stock Change Data Release on September 9, 2026, Expected to Reflect Volatile U.S. Inventory Trends Amid Geopolitical Tensions and OPEC+ Production Stability.

2026-09-06 18:51; UTC

Italy's Industrial Production Expected to Rise 0.3% in July Amidst Recent Declines and Economic Concerns

2026-09-06 18:31; UTC

France's Industrial Production Expected to Rise 0.3% in July Amid Economic Uncertainty

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

93.05% į viršų

12 mėnesių prognozė

Vidutinis 5 USD 93.05%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Compugen Ltd akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.